Physician profile
Daniel Macias
NPI 1184734675
$685,789.97
in general payments reported to CMS, 2019-2025
23 companies · $38K in 2025
The $38K reported for 2025 was more than what 95% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $209K · 2020: $100K · 2021: $93K · 2022: $112K · 2023: $82K · 2024: $51K · 2025: $38K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $156K · Travel and Lodging: $8,951 · Food and Beverage: $5,279 · Education: $125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $156,475.00 |
| Travel and Lodging | $8,951.05 |
| Food and Beverage | $5,279.49 |
| Education | $125.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $447,000.35 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Sanofi-Aventis U.S. LLC | $111,153.92 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $66,618.06 | 2019-2023 | Jardiance, Ofev |
| Novo Nordisk INC | $56,576.09 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Abbott Laboratories | $1,758.72 | 2019-2025 | Freestyle Libre 3 |
| Dexcom, INC. | $729.13 | 2021-2024 | Dexcom G6 Transmitter |
| Janssen Pharmaceuticals, INC | $368.42 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $308.68 | 2020-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $296.65 | 2022-2024 | |
| Medtronic, INC. | $225.10 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $198.31 | 2020-2023 | Breztri |
| Insulet Corporation | $165.62 | 2019-2024 | Omnipod |
| Abbvie INC. | $112.28 | 2023-2025 | |
| Amarin Pharma, INC. | $61.47 | 2020 | |
| Esperion Therapeutics, INC. | $45.79 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $36.83 | 2025 | Evenity |
| Globus Medical, INC. | $36.38 | 2025 | Senza |
| Cequr Corporation | $23.00 | 2023 | Cequr Simplicity |
| Medtronic Minimed, INC. | $16.84 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.67 | 2020 | |
| Pfizer INC. | $14.99 | 2024 | |
| Sunovion Pharmaceuticals INC. | $13.57 | 2021 | |
| Vifor Pharma, INC. | $13.10 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Macias listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.